Literature DB >> 14982809

Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.

Rose Jung1, Maroof Husain, Michael K Choi, Douglas N Fish.   

Abstract

The bactericidal activity of moxifloxacin alone and in combination with cefepime or piperacillin-tazobactam against clinical isolates of Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii was evaluated by using time-kill methods and antimicrobial concentrations of one-half and one times the MIC. Synergy was observed in 58 to 88% of the strains and resulted in bactericidal activity against 60 to 100% of the strains. Combinations including moxifloxacin demonstrated enhanced bactericidal activity compared with that of either agent tested alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982809      PMCID: PMC353069          DOI: 10.1128/AAC.48.3.1055-1057.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System.

Authors: 
Journal:  Am J Infect Control       Date:  1999-12       Impact factor: 2.918

2.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 4.  Moxifloxacin.

Authors:  J A Balfour; L R Wiseman
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

5.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

  5 in total
  6 in total

Review 1.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

2.  Hydroxyl radicals are involved in cell killing by the bacterial topoisomerase I cleavage complex.

Authors:  I-Fen Liu; Thirunavukkarasu Annamalai; Jeanette H Sutherland; Yuk-Ching Tse-Dinh
Journal:  J Bacteriol       Date:  2009-06-12       Impact factor: 3.490

3.  Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae.

Authors:  Thais Bergamin Lima; Osmar Nascimento Silva; Keyla Caroline de Almeida; Suzana Meira Ribeiro; Dielle de Oliveira Motta; Simone Maria-Neto; Michelle Brizolla Lara; Carlos Roberto Souza Filho; Alicia Simalie Ombredane; Celio de Faria Junior; Nadia Skorupa Parachin; Beatriz Simas Magalhães; Octávio Luiz Franco
Journal:  J Antibiot (Tokyo)       Date:  2016-07-06       Impact factor: 2.649

Review 4.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 6.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.